269 related articles for article (PubMed ID: 25732645)
1. Cabergoline use for pituitary tumors and valvular disorders.
Auriemma RS; Pivonello R; Ferreri L; Priscitelli P; Colao A
Endocrinol Metab Clin North Am; 2015 Mar; 44(1):89-97. PubMed ID: 25732645
[TBL] [Abstract][Full Text] [Related]
2. Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas.
Auriemma RS; Pivonello R; Perone Y; Grasso LF; Ferreri L; Simeoli C; Iacuaniello D; Gasperi M; Colao A
Eur J Endocrinol; 2013 Sep; 169(3):359-66. PubMed ID: 23824978
[TBL] [Abstract][Full Text] [Related]
3. Optimal effective doses of cabergoline and bromocriptine and valvular leasions in men with prolactinomas.
Yarman S; Kurtulmus N; Bilge A
Neuro Endocrinol Lett; 2012; 33(3):340-6. PubMed ID: 22635095
[TBL] [Abstract][Full Text] [Related]
4. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma.
Kars M; Delgado V; Holman ER; Feelders RA; Smit JW; Romijn JA; Bax JJ; Pereira AM
J Clin Endocrinol Metab; 2008 Sep; 93(9):3348-56. PubMed ID: 18559921
[TBL] [Abstract][Full Text] [Related]
5. Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required.
Kars M; Pereira AM; Bax JJ; Romijn JA
Eur J Endocrinol; 2008 Oct; 159(4):363-7. PubMed ID: 18703568
[TBL] [Abstract][Full Text] [Related]
6. The cabergoline-resistant prolactinoma patient: new challenges.
Molitch ME
J Clin Endocrinol Metab; 2008 Dec; 93(12):4643-5. PubMed ID: 19056842
[No Abstract] [Full Text] [Related]
7. The safety of treatments for prolactinomas.
Auriemma RS; Grasso LF; Pivonello R; Colao A
Expert Opin Drug Saf; 2016; 15(4):503-12. PubMed ID: 26855238
[TBL] [Abstract][Full Text] [Related]
8. The need for annual echocardiography to detect cabergoline-associated valvulopathy in patients with prolactinoma: a systematic review and additional clinical data.
Caputo C; Prior D; Inder WJ
Lancet Diabetes Endocrinol; 2015 Nov; 3(11):906-13. PubMed ID: 25466526
[TBL] [Abstract][Full Text] [Related]
9. Low-dose cabergoline causing valvular heart disease in a patient treated for prolactinoma.
Cawood TJ; Bridgman P; Hunter L; Cole D
Intern Med J; 2009 Apr; 39(4):266-7. PubMed ID: 19402868
[No Abstract] [Full Text] [Related]
10. Cabergoline therapy for prolactinomas: is valvular heart disease a real safety concern?
Vallette S; Serri K; Serri O
Expert Rev Cardiovasc Ther; 2010 Jan; 8(1):49-54. PubMed ID: 20014934
[TBL] [Abstract][Full Text] [Related]
11. Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment.
Elenkova A; Shabani R; Kalinov K; Zacharieva S
Eur J Endocrinol; 2012 Jul; 167(1):17-25. PubMed ID: 22511808
[TBL] [Abstract][Full Text] [Related]
12. Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia.
Vroonen L; Lancellotti P; Garcia MT; Dulgheru R; Rubio-Almanza M; Maiga I; Magne J; Petrossians P; Auriemma R; Daly AF; Beckers A
Endocrine; 2017 Jan; 55(1):239-245. PubMed ID: 27709470
[TBL] [Abstract][Full Text] [Related]
13. Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis.
Hu J; Zheng X; Zhang W; Yang H
Pituitary; 2015 Oct; 18(5):745-51. PubMed ID: 25500765
[TBL] [Abstract][Full Text] [Related]
14. Dopamine agonists and valvular heart disease.
Cheung D; Heaney A
Curr Opin Endocrinol Diabetes Obes; 2009 Aug; 16(4):316-20. PubMed ID: 19506475
[TBL] [Abstract][Full Text] [Related]
15. Autoimmune Fibrotic Adverse Reactions in One-Year Treatment with Cabergoline for Women with Prolactinoma.
Doğan BA; Arduc A; Tuna MM; Berker D; Demirci N; Demirtaş S; Çiçekcioğlu H; Güler S
Endocr Metab Immune Disord Drug Targets; 2016; 16(1):47-55. PubMed ID: 26924497
[TBL] [Abstract][Full Text] [Related]
16. Changes in heart valve structure and function in patients treated with dopamine agonists for prolactinomas, a 2-year follow-up study.
Delgado V; Biermasz NR; van Thiel SW; Ewe SH; Marsan NA; Holman ER; Feelders RA; Smit JW; Bax JJ; Pereira AM
Clin Endocrinol (Oxf); 2012 Jul; 77(1):99-105. PubMed ID: 22211510
[TBL] [Abstract][Full Text] [Related]
17. Medical approach to pituitary tumors.
Neggers SJ; van der Lely AJ
Handb Clin Neurol; 2014; 124():303-16. PubMed ID: 25248595
[TBL] [Abstract][Full Text] [Related]
18. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma.
Herring N; Szmigielski C; Becher H; Karavitaki N; Wass JA
Clin Endocrinol (Oxf); 2009 Jan; 70(1):104-8. PubMed ID: 19128367
[TBL] [Abstract][Full Text] [Related]
19. Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline.
Lafeber M; Stades AM; Valk GD; Cramer MJ; Teding van Berkhout F; Zelissen PM
Eur J Endocrinol; 2010 Apr; 162(4):667-75. PubMed ID: 20071478
[TBL] [Abstract][Full Text] [Related]
20. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.
Antonini A; Poewe W
Lancet Neurol; 2007 Sep; 6(9):826-9. PubMed ID: 17706566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
